BioCatalystFeed / Readout calendar / FDA decisions / Drugs / Disease areas / Companies / Months

NVS upcoming catalysts

Novartis Pharmaceuticals: 11 upcoming industry Phase 2/3 trial readout(s) in the next 90 days (3 Phase 3), 0 upcoming FDA decision event(s), and in the last 12 months 30 readout(s) and 12 FDA event(s). Subscribe to NVS (.ics).

Drugs: Iptacopan, AAA617, JDQ443, KAE609, Remibrutinib, Alpelisib, Fulvestrant, Ribociclib, KLU156, Teriflunomide, INE963, JSB462, Abiraterone, Enzalutamide, AAA517, Piflufolastat F 18, ARPI, ADT, Rituximab, Inclisiran, TNO155, tislelizumab, LEE011, LXH254, LTT462, Trametinib, 68Ga-PSMA-11, Corticosteroids, cetuximab, docetaxel

Upcoming FDA decision events

DateEventStatusCompanyDrugSource
No upcoming PDUFA date or AdCom found.

Upcoming trial readouts

ReadoutPhaseSponsorTrialConditionsStatusEnrollment
2026-12-03 est.P2Novartis Pharmaceuticals NVSNCT06991556 An Open-label Study of JSB462 (Luxdegalutamide) in Combination With Abiraterone in Adult Male Patients With Metastatic Hormone-sensitive Prostate Cancer (mHSPC)Metastatic Hormone-sensitive Prostate Canceractive not recruiting168
2026-12-23 est.P2Novartis Pharmaceuticals NVSNCT05849298 A Phase II Study of AAA617 Alone and AAA617 in Combination With ARPI in Patients With PSMA PET Scan Positive CRPCProstatic Neoplasmactive not recruiting49
2026-12-30 est.P2Novartis Pharmaceuticals NVSNCT06388941 Iptacopan in Patients With ANCA Associated VasculitisAnti-Neutrophil Cytoplasm Antibodies (ANCA) Associated Vasculitisactive not recruiting84
2027-01-16 est.P3Novartis Pharmaceuticals NVSNCT07102628 Evaluation of Efficacy and Safety of Early in Hospital Initiation of Inclisiran Treatment in Patients With Acute Coronary SyndromesAcute Coronary Syndromeactive not recruiting305
2027-01-25 est.P1/P2Novartis Pharmaceuticals NVSNCT04699188 Study of JDQ443 in Patients With Advanced Solid Tumors Harboring the KRAS G12C MutationKRAS G12C Mutant Solid Tumors; Carcinoma, Non-Small-Cell Lung; Carcinoma, Colorectal; Cancer of Lungactive not recruiting344
2027-01-28 est.P3Novartis Pharmaceuticals NVSNCT05038735 Study to Assess the Efficacy and Safety of Alpelisib Plus Fulvestrant in Participants With HR-positive (HR+), HER2-negative, Advanced Breast Cancer After TreatmBreast Canceractive not recruiting210
2027-01-29 est.P2Novartis Pharmaceuticals NVSNCT04544189 Study Assessing the Efficacy and Safety of Treatment With Alpelisib Plus Fulvestrant Versus Placebo Plus Fulvestrant in Chinese Men and Postmenopausal Women WitBreast Neoplasmsactive not recruiting69
2027-01-29 est.P3Novartis Pharmaceuticals NVSNCT04817618 Study of Efficacy and Safety of Iptacopan in Patients With C3 Glomerulopathy.C3Grecruiting98
2027-02-01 est.P2Novartis Pharmaceuticals NVSNCT02934568 Ribociclib (LEE011) Rollover Study for Continued AccessContinued Access to Study Treatment(s), Cancers With a Mass, Bulky Tumor, Nodule, Lump, Advanced Canactive not recruiting22
2027-02-02 est.P2Novartis Pharmaceuticals NVSNCT04417621 Study of Efficacy and Safety of LXH254 Combinations in Patients With Previously Treated Unresectable or Metastatic MelanomaMelanomaactive not recruiting134
2027-02-04 est.P2Novartis Pharmaceuticals NVSNCT07811908 Platform Study to Evaluate the Efficacy and Safety of Anti-malarial Agents in Participants With Uncomplicated Plasmodium Falciparum Malaria (Cohort C2)Uncomplicated Plasmodium Falciparum Malariarecruiting120

FDA decision events, last 12 months

DateEventStatusCompanyDrugSource
2026-10-15FDA approvalapprovedNOVARTIS PHARMS CORP NVSCOSENTYXApproved 2026-10-15: COSENTYX (BLA761349 SUPPL13)
2026-10-06FDA approvalapprovedNOVARTIS NVSRHAPSIDOApproved 2026-10-06: RHAPSIDO (NDA218436 SUPPL1)
2026-07-31FDA approvalapprovedNOVARTIS NVSPLUVICTOApproved 2026-07-31: PLUVICTO (NDA215833 SUPPL37)
2026-07-16FDA approvalapprovedNOVARTIS NVSFABHALTAApproved 2026-07-16: FABHALTA (NDA218276 SUPPL7)
2026-07-01FDA approvalapprovedNOVARTIS NVSKISQALI FEMARA CO-PACKApproved 2026-07-01: KISQALI FEMARA CO-PACK (COPACKAGED) (NDA209935 SUPPL33)
2026-07-01FDA approvalapprovedNOVARTIS NVSKISQALIApproved 2026-07-01: KISQALI (NDA209092 SUPPL27)
2026-04-17FDA approvalapprovedNOVARTIS PHARMS CORP NVSCOSENTYXApproved 2026-04-17: COSENTYX (BLA125504 SUPPL97)
2026-04-17FDA approvalapprovedNOVARTIS PHARMS CORP NVSCOSENTYXApproved 2026-04-17: COSENTYX (BLA125504 SUPPL98)
2026-03-12FDA approvalapprovedNOVARTIS PHARMS CORP NVSCOSENTYXApproved 2026-03-12: COSENTYX (BLA125504 SUPPL91)
2026-02-12FDA approvalapprovedNOVARTIS NVSLEQVIOApproved 2026-02-12: LEQVIO (NDA214012 SUPPL18)
2026-02-12FDA approvalapprovedNOVARTIS NVSLEQVIOApproved 2026-02-12: LEQVIO (NDA214012 SUPPL17)
2025-11-25FDA approvalapprovedNOVARTIS NVSSCEMBLIXApproved 2025-11-25: SCEMBLIX (NDA215358 SUPPL12)

Trial readouts, last 12 months

ReadoutPhaseSponsorTrialConditionsStatusEnrollment
2026-11-17 est.P2Novartis Pharmaceuticals NVSNCT06894511 An Open-label Study of Lutetium (177Lu) Vipivotide Tetraxetan (AAA617) in Combination With ARPI Versus AAA617 in PSMA Positive First-line mCRPCMetastatic Castration Resistant Prostate Cancer (mCRPC)active not recruiting7
2026-11-06 est.P2Novartis Pharmaceuticals NVSNCT06004661 Study of Lutetium (177Lu) Vipivotide Tetraxetan in mCRPC Participants With Moderately and Severely Impaired and With Normal Renal FunctionMetastatic Castration-Resistant Prostate Cancer (mCRPC)active not recruiting23
2026-11-03 est.P3Novartis Pharmaceuticals NVSNCT05677451 24 Weeks Double-blind Randomized Placebo-controlled Trial to Evaluate Efficacy, PK, Safety of LOU064 in Adolescents (12 - <18) With CSU and Inadequate Response Chronic Spontaneous Urticariaactive not recruiting100
2026-10-29P3Novartis Pharmaceuticals NVSNCT05653349 Study of Ianalumab Versus Placebo in Addition to First-line Corticosteroids in Primary Immune Thrombocytopenia (ITP)Primary Immune Thrombocytopenia (ITP)active not recruiting226
2026-10-26 est.P3Novartis Pharmaceuticals NVSNCT05360446 Coronary Computed Tomography Study to Assess the Effect of Inclisiran in Addition to Maximally Tolerated Statin Therapy on Atherosclerotic Plaque Progression inCoronary Artery Diseaseactive not recruiting610
2026-10-15P3Novartis Pharmaceuticals NVSNCT05900141 An Open Label Extension (OLE) Study to Evaluate Long-term Safety and Tolerability of Pelacarsen (TQJ230)Hyperlipoproteinemia (a)terminated41
2026-09-28P1/P2Novartis Pharmaceuticals NVSNCT05358249 Platform Study of JDQ443 in Combinations in Patients With Advanced Solid Tumors Harboring the KRAS G12C MutationKRAS G12C Mutant Solid Tumors; Carcinoma, Non-Small Cell Lung; Carcinoma, Non-Small-Cell Lung; Non-Sterminated74
2026-09-24P1/P2Novartis Pharmaceuticals NVSNCT05798117 An Open-label, Study to Assess Safety, Efficacy and Cellular Kinetics of YTB323 in Severe, Refractory Systemic Lupus ErythematosusSystemic Lupus Erythematosus; Lupus Nephritiscompleted21
2026-09-17P2Novartis Pharmaceuticals NVSNCT06857955 A Study to Identify an Optimal Dose of QCZ484 in Mild to Moderate Hypertensive PatientsHypertensionactive not recruiting396
2026-09-03P3Novartis Pharmaceuticals NVSNCT05132075 Study of JDQ443 in Comparison With Docetaxel in Participants With Locally Advanced or Metastatic KRAS G12C Mutant Non-small Cell Lung CancerNon-Small Cell Lung Cancerterminated95
2026-08-19P2Novartis Pharmaceuticals NVSNCT05230537 A Masked, Placebo-controlled Study to Assess Iptacopan in Age-related Macular DegenerationAge-Related Macular Degenerationcompleted168
2026-07-22P3Novartis Pharmaceuticals NVSNCT05156281 Efficacy and Safety of Remibrutinib Compared to Teriflunomide in Participants With Relapsing Multiple Sclerosis (RMS)Relapsing Multiple Sclerosisactive not recruiting1007
2026-07-21P3Novartis Pharmaceuticals NVSNCT05147220 Efficacy and Safety of Remibrutinib Compared to Teriflunomide in Participants With Relapsing Multiple Sclerosis (RMS) (REMODEL-1)Relapsing Multiple Sclerosisactive not recruiting1000
2026-07-16P3Novartis Pharmaceuticals NVSNCT04023552 Assessing the Impact of Lipoprotein (a) Lowering With Pelacarsen (TQJ230) on Major Cardiovascular Events in Patients With CVDCardiovascular Disease and Lipoprotein(a)completed8323
2026-06-23P2Novartis Pharmaceuticals NVSNCT06643481 A Clinical Trial to Learn About the Effects of VHB937 in People With Amyotrophic Lateral Sclerosis (ALS)Amyotrophic Lateral Sclerosis (ALS)active not recruiting251
2026-06-17P2Novartis Pharmaceuticals NVSNCT07811882 Platform Study to Evaluate the Efficacy and Safety of Anti-malarial Agents in Participants With Uncomplicated Plasmodium Falciparum Malaria (Cohort B1)Uncomplicated Plasmodium Falciparum Malariacompleted95
2026-06-10P1/P2Novartis Pharmaceuticals NVSNCT03945318 Safety and Tolerability of BION-1301 in Healthy Volunteers and Adults With IgA Nephropathy (IgAN)IgA Nephropathycompleted103
2026-06-09 est.P2Novartis Pharmaceuticals NVSNCT05750628 Platform Study to Evaluate the Efficacy and Safety of Anti-malarial Agents in Patients With Uncomplicated Plasmodium Falciparum MalariaUncomplicated Plasmodium Falciparum Malariarecruiting327
2026-05-12P1/P2Novartis Pharmaceuticals NVSNCT03374657 A First-in-human, Proof of Concept Study of CPK850 in Patients With RLBP1 Retinitis PigmentosaRetinitis Pigmentosacompleted12
2026-05-11P3Novartis Pharmaceuticals NVSNCT05976243 A Study to Investigate Efficacy, Safety, and Tolerability of Remibrutinib Compared With Placebo in Adults With CINDU Inadequately Controlled by H1-antihistamineChronic Inducible Urticariaactive not recruiting362
2026-04-11P3Novartis Pharmaceuticals NVSNCT04889430 Efficacy and Safety of Iptacopan (LNP023) in Adult Patients With Atypical Hemolytic Uremic Syndrome Naive to Complement Inhibitor TherapyAtypical Hemolytic Uremic Syndromecompleted34
2026-03-25P3Novartis Pharmaceuticals NVSNCT06267560 Lp(a) Lowering Study of Pelacarsen (TQJ230) in US Black/African American and Hispanic Participants With Elevated Lp(a) and Established ASCVDElevated Lp(a) and Established Atherosclerotic Cardiovascular Diseasecompleted422
2026-03-25P3Novartis Pharmaceuticals NVSNCT04926818 Efficacy and Safety of Ofatumumab and Siponimod Compared to Fingolimod in Pediatric Patients With Multiple SclerosisMultiple Sclerosis (MS)active not recruiting129
2026-03-19P2Novartis Pharmaceuticals NVSNCT05268289 Study of Efficacy and Safety of LNP023 in Participants With Active Lupus Nephritis Class III-IV, +/- VLupus Nephritisterminated81
2026-02-25P2Novartis Pharmaceuticals NVSNCT05996835 Phase 2b Study to Investigate the Safety and Efficacy of TIN816 in Sepsis-associated Acute Kidney Injury (CLEAR-AKI)Acute Kidney Injury Due to Sepsiscompleted316
2026-02-24P3Novartis Pharmaceuticals NVSNCT05380453 Efficacy and Safety of Secukinumab in Patients With New Onset of Giant Cell Arteritis Who Are in Clinical RemissionGiant Cell Arteritiscompleted151
2026-02-20P3Novartis Pharmaceuticals NVSNCT05648968 A Study of Efficacy and Safety of Ianalumab in Previously Treated Patients With Warm Autoimmune Hemolytic AnemiaWarm Autoimmune Hemolytic Anemia (wAIHA)active not recruiting90
2026-02-17P2Novartis Pharmaceuticals NVSNCT06293365 Two-period Crossover Study to Demonstrate the Comparability of Pharmacokinetics of Subcutaneous Ianalumab Between 2mL Auto-injector/2mL PFS with1mL Pre-filled SSjögrens Disease; Systemic Lupus Erythematosus; Rheumatoid Arthritisactive not recruiting155
2026-02-03P2Novartis Pharmaceuticals NVSNCT05592990 A Study to Investigate the Safety, Tolerability and Preliminary Efficacy of NGI226 Microparticles in Patients With Achilles TendinopathyAchilles Tendinopathycompleted45
2026-01-28P3Novartis Pharmaceuticals NVSNCT06869785 Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of a New Maintenance Dosing Regimen of OfatumumabRelapsing Multiple Sclerosis (RMS)active not recruiting196

Readout = ClinicalTrials.gov primary completion date (sponsor-reported; est. dates often slip; top-line results usually follow weeks to months later). FDA events: PDUFA dates are extracted from company 8-K filings (SEC EDGAR) and are company-disclosed and UNVERIFIED - read the filing; AdCom meetings come from Federal Register notices; approvals from Drugs@FDA (openFDA); complete response letters from openFDA (published with a lag). Tickers are matched by name with a confidence score. Generated 2026-11-18T17:57:33Z. Same data: bcf readouts search, bcf fda-decisions search, MCP readout_calendar / fda_decisions. Not investment advice.